Unknown

Dataset Information

0

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.

ABSTRACT:

SUBMITTER: Doria-Rose N 

PROVIDER: S-EPMC8524784 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown B-cell responses to vaccination with BNT162b2 and mRNA-1273 6 months after second dose.
| S-EPMC8897957 | biostudies-literature
Unknown Case report: acute myocarditis following the second dose of mRNA-1273 SARS-CoV-2 vaccine.
| S-EPMC8422333 | biostudies-literature
Unknown Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients.
| S-EPMC10818923 | biostudies-literature
Unknown Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells.
| S-EPMC8542617 | biostudies-literature
Unknown Antibody Response against Circulating Omicron Variants 8 Months after the Third Dose of mRNA Vaccine.
| S-EPMC9501623 | biostudies-literature
Unknown BNT162b2 versus mRNA-1273 Third Dose COVID-19 Vaccine in Patients with CKD and Maintenance Dialysis Patients.
| S-EPMC10843183 | biostudies-literature
Unknown Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
| S-EPMC8842222 | biostudies-literature
Unknown Immunostimulatory/Immunodynamic model of mRNA-1273 to guide pediatric vaccine dose selection.
| S-EPMC11706428 | biostudies-literature
Unknown Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age.
| S-EPMC9634866 | biostudies-literature
Unknown Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial.
| S-EPMC10243212 | biostudies-literature